AU2002220702A1 - Quinoline derivatives as nk-3 and nk-2 antagonists - Google Patents

Quinoline derivatives as nk-3 and nk-2 antagonists

Info

Publication number
AU2002220702A1
AU2002220702A1 AU2002220702A AU2070202A AU2002220702A1 AU 2002220702 A1 AU2002220702 A1 AU 2002220702A1 AU 2002220702 A AU2002220702 A AU 2002220702A AU 2070202 A AU2070202 A AU 2070202A AU 2002220702 A1 AU2002220702 A1 AU 2002220702A1
Authority
AU
Australia
Prior art keywords
antagonists
quinoline derivatives
quinoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220702A
Inventor
Carlo Farina
Stefania Gagliardi
Giuseppe Giardina
Mario Grugni
Marisa Martinelli
Guy Marguerite Marie Gerard Nadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire GlaxoSmithKline SAS
GlaxoSmithKline SpA
Original Assignee
Laboratoire GlaxoSmithKline SAS
GlaxoSmithKline SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0027696A external-priority patent/GB0027696D0/en
Application filed by Laboratoire GlaxoSmithKline SAS, GlaxoSmithKline SpA filed Critical Laboratoire GlaxoSmithKline SAS
Publication of AU2002220702A1 publication Critical patent/AU2002220702A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002220702A 2000-11-13 2001-11-12 Quinoline derivatives as nk-3 and nk-2 antagonists Abandoned AU2002220702A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0027696A GB0027696D0 (en) 2000-11-13 2000-11-13 Novel compounds
GB0027696 2000-11-13
GB0109119 2001-04-11
GB0109119A GB0109119D0 (en) 2000-11-13 2001-04-11 Novel compounds
PCT/EP2001/013139 WO2002038547A1 (en) 2000-11-13 2001-11-12 Quinoline derivatives as nk-3 and nk-2 antagonists

Publications (1)

Publication Number Publication Date
AU2002220702A1 true AU2002220702A1 (en) 2002-05-21

Family

ID=26245280

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220702A Abandoned AU2002220702A1 (en) 2000-11-13 2001-11-12 Quinoline derivatives as nk-3 and nk-2 antagonists

Country Status (5)

Country Link
US (2) US20040082589A1 (en)
EP (1) EP1334089A1 (en)
JP (1) JP2004517062A (en)
AU (1) AU2002220702A1 (en)
WO (1) WO2002038547A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
US20060111368A1 (en) * 2002-06-26 2006-05-25 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
US20070060593A1 (en) * 2003-06-25 2007-03-15 Kerns Jeffrey K 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3
CA2565018A1 (en) 2004-04-28 2005-11-10 Takeda Pharmaceutical Company Limited Fused quinoline derivative and use thereof
MX2007007428A (en) * 2004-12-24 2007-07-16 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists.
GB0428327D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Ab Method
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
GB0525957D0 (en) * 2005-12-21 2006-02-01 Astrazeneca Ab Methods
AR069526A1 (en) 2007-12-03 2010-01-27 Takeda Pharmaceutical HETEROCICLICAL COMPOUND CONTAINING NITROGEN AND ITS USE
EP2336105B9 (en) 2008-09-19 2014-09-17 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004735A1 (en) * 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
AP9901695A0 (en) * 1997-05-23 1999-12-31 Smithkline Beecham Spa Quinoline-4-carbaoxamide derivatives as NK-2 and NK-3 receptor antagonists.
JP2002530377A (en) * 1998-11-20 2002-09-17 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists

Also Published As

Publication number Publication date
WO2002038547A1 (en) 2002-05-16
EP1334089A1 (en) 2003-08-13
JP2004517062A (en) 2004-06-10
US20040082589A1 (en) 2004-04-29
US20070015766A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
HK1074176A1 (en) Quinoline derivatives as neuropeptide y antagonists
AU1047402A (en) Quinoline and quinazoline derivatives
PL347721A1 (en) Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
HK1089438A1 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
IL175947A0 (en) Novel quinoline derivatives
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
HK1053644A1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
MXPA02008402A (en) Derivatives of quinoline as alpha-2 antagonists.
AU2001295791A1 (en) 4-substituted quinolines as antitumor agents
EP1408971A4 (en) Novel quinolines and uses thereof
IL133036A0 (en) Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists
AU2002347336A1 (en) Quinoline derivatives
AU2002215043A1 (en) Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
AU2002220702A1 (en) Quinoline derivatives as nk-3 and nk-2 antagonists
AU2002226356A1 (en) Quinoline derivatives as nk-3 antagonists
AU2002347359A1 (en) Quinoline derivatives
WO2002047456A3 (en) Urotensin-ii receptor antagonists
AU2003274551A1 (en) Quinoline derivatives
AU2002365664A1 (en) Quinoline derivatives as antitumour agents
AU2002302735A1 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
PL370915A1 (en) Quinoline derivatives
AU2002216939A1 (en) Quinoline derivatives and their use as anti-epileptics
AU2002310838A1 (en) Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
AU2002308138A1 (en) 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
AU2002247737A1 (en) Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone